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© Qalys Health Economics 2008Background
 WHO recommendation to replace d4T
 Scaling-up
 Problem: How much will it cost?
 Tool: Health economic model
© Qalys Health Economics 2008Objectives
Develop a model to:
 Support decision making
 Demonstrate budget impacts
 Compare timing of introdcution
 Forecast ART budget 2008 - 2014
© Qalys Health Economics 2008Tenofovir vs. Stavudine
Tenofovir (TDF)
 WHO recommendation
 Better toxicity profile
 Once a day dosing
 TDF $128 PPY
Stavudine (d4T)
 d4T $19 PPY
 Significant toxicitìes
 Fixed dose combination:
d4T / 3TC / NVP 
30mg / 150mg / 200mg
© Qalys Health Economics 2008Current first-line regimen
3TC
d4T NVP
© Qalys Health Economics 2008New improved first-line regimen
3TC
d4T NVP
TDF EFV
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© Qalys Health Economics 2008ART survival and 2nd-line switch rate
 Global Cohort MSF
57.000 ART patients
 Extrapolated after 48 
months
 ART survival 9.7 years
 2nd-line switching rate 
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Epworth, Harare township
 Population 400.000
 20% infected with HIV
MSF program
 6.000 HIV+ patients 
 1.400 on ART
 First ARTs April 2007
 150 new patients / month
© Qalys Health Economics 2008150 new ART patients / month
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 Patient volume
Nr of patients, speed of scaling-up
 Medical data
ART regimens, ART survival, rate of switch to 2nd-line, CD4 baselines
 Financial information
Forecasted ART prices, actual expenditures, annual budget
 Sensitivity analyses
© Qalys Health Economics 2008Base case: All patients on d4T/3TC/NVP 
$1.8M
© Qalys Health Economics 2008All patients on TDF/3TC/EFV 2008
$8.8M
$1.8M
© Qalys Health Economics 2008Only new patients on TDF/3TC/EFV 2008
$7.6M
$8.8M
$1.8M
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$1.8M
© Qalys Health Economics 2008Only new patients on TDF/3TC/EFV 2009
$6.1M
$8.8M
$1.8M
© Qalys Health Economics 2008Only new patients on TDF/3TC/EFV 2010
$4.7M
$8.8M
$1.8M
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3TC
d4T NVP
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3TC
d4T NVP
TDF
© Qalys Health Economics 2008All patients on TDF/3TC/NVP 2008
$6.6M
$1.8M
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Cipla 19 USD d4T
Aubindo
Hetero
61 USD 82 USD
87 USD
d4T/3TC/NVP
Matrix
Cipla
365 USD
350 USD KIT
FDC TDF/3TC/
EFV
Hetero 101 USD 146 USD EFAVIRENZ
Cipla 27 USD 35 USD LAMIVUDINE
Hetero 88 USD 128 USD TENOFOVIR
Manufacturer Price in 2014 Current price Drug
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 Potential cost savings:
from better toxicity profile of TDF
 ART price development
 Inadequate TDF survival data
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 Useful tool to forecast costs:
ART regimen changes
Scaling-up
Higher CD4 threshold
Forecasting human resource needs
 High cost of TDF and EFV
 Major barrier in resource poor settings
© Qalys Health Economics 2008Field team
Epworth
Zimbabwe
Kalpana 
Sabapathy
HIV/AIDS Advisor
MSF-OCA
Clair Mills
Medical Director
MSF-OCA 
Daniel O'Brien
HIV/AIDS Advisor 
MSF-OCA
Jari Kivela
Health Economist
+31 20 8508497
jari.kivela@qalys.eu
© Qalys Health Economics 2008